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exoskeleton home and community 
use in people with complete spinal 
cord injury
Rosanne B. van Dijsseldonk1,2*, Ilse J. W. van Nes3, Alexander C. H. Geurts1,3 & 
Noël L. W. Keijsers1,2
A consequence of a complete spinal cord injury (SCI) is the loss of gait capacity. Wearable exoskeletons 
for the lower extremity enable household and community ambulation in people with SCI. This 
study assessed the amount, purpose, and location of exoskeleton use in the home and community 
environment, without any restrictions. The number of steps taken was read from the exoskeleton 
software. Participants kept a daily logbook, and completed two user experience questionnaires 
(Quebec User Evaluation of Satisfaction with assistive Technology (D-QUEST) and System Usability 
Scale (SUS)). Fourteen people with a complete SCI used the ReWalk exoskeleton a median of 9 (range 
[1–15]) out of 16 ([12–21]) days, in which participants took a median of 3,226 ([330–28,882]) steps. 
The exoskeleton was mostly used for exercise purposes (74%) and social interaction (20%). The 
main location of use was outdoors (48%). Overall, participants were satisfied with the exoskeleton 
(D-QUEST 3.7 ± 0.4) and its usability (SUS 72.5 [52.5–95.0]). Participants with complete SCI report 
satisfaction with the exoskeleton for exercise and social interaction in the home and community, but 
report limitations as an assistive device during daily life.
The incidence of spinal cord injury (SCI) is approximately 180,000 cases per year  worldwide1. Half of the people 
with SCI have a complete  lesion2, which has a huge impact on their daily  lives3. For mobility, a manual wheelchair 
is the most common option. Over the last decade, an alternative locomotion option for people with SCI was 
introduced: a wearable exoskeleton. With an external active orthosis and supported by two crutches, the basic 
motions for ambulation (i.e., standing-up, sitting-down, standing, and walking) can be initiated and controlled.
Until now, exoskeletons are mostly used in clinical settings, which has been shown to be feasible and safe for 
a broad range of patients with  SCI4,5. As a gait retraining device, the exoskeleton is used to improve ambulatory 
capacity in patients with some residual leg motor function or in those for whom functional recovery is still pos-
sible (i.e., incomplete SCI). The potential of an exoskeleton for gait restoration was demonstrated by improving 
unassisted gait speed and walking distance after exoskeleton  training6. Furthermore, two non-walkers with an 
incomplete SCI became walkers after exoskeleton  training4,7. Hence, for people with incomplete SCI, ‘therapeutic’ 
exoskeleton use has the potential to improve ambulatory capacity independent of the exoskeleton.
In patients without (the potential for) ambulatory capacity (i.e., complete SCI), who are wheelchair users for 
their mobility, an exoskeleton can be used as an assistive device in order to walk. However, exoskeleton use as an 
assistive device without physical assistance from a trainer requires an intensive training  period7–9. In our previ-
ous study, we have shown that more than half of the participants with a complete SCI could use an exoskeleton 
independent of assistance under supervision of a buddy after 24 training  sessions9. Moreover, most of these par-
ticipants were able to perform multiple advanced skills during independent walking (e.g. walking up and over a 
sloping doorstep) and standing (e.g. moving a cone at chest height)9,10, which strengthens the idea of exoskeleton 
home use during some daily activities. Another advantage of exoskeleton use are the potential health  benefits11,12. 
Because of the possibility to stand and walk in an upright position, exoskeletons may help to prevent secondary 
health complications, such as  spasticity11,12, impaired bowel  function13, and related loss of quality of  life11. From 
this perspective, exoskeletons are used as an exercise device to promote physical health and well-being by reduc-
ing secondary health complications. However, to actually reduce secondary health complications, the frequency 
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and intensity of exoskeleton use are critical. The intensity of walking with an exoskeleton is similar to regular 
physical activities performed at a moderate  intensity14,15, which is known to yield health  benefits12. In contrast 
to the use of conventional knee–ankle–foot–orthoses, the use of exoskeletons is not physically  exhausting16,17, 
which is why they can be used more  regularly14. This strengthens the idea of continued exoskeleton use at home 
and/or in the  community18.
To date, one study described a gym-based setting for exoskeleton  use19. To our knowledge, no other studies 
have been described for the use of exoskeletons outside the clinical setting. Instead of in the actual home and 
community environment, exoskeleton use was investigated in a gym-based setting. Four participants with SCI 
were interviewed and reported that gym-based exoskeleton use had a positive impact on their lives and enhanced 
their perceived wellbeing and sense of community  integration19. Yet, daily life entails much more than just the 
usage in a gym-based setting. According to Fritz et al.20, home and community use entails engaging in age nor-
mative and meaningful activities such as meeting friends at a pub, attending a graduation ceremony, perform-
ing one’s job, or going on  holiday20. In addition to these social activities, home and community use also entails 
household chores such as cooking or doing the laundry. The question thus remains whether exoskeletons are 
already applicable in these  settings21. Up to now, the applicability and effectiveness of exoskeletons in the com-
munity have not been demonstrated. Some expected challenges for community exoskeleton use are the limited 
gait speed, the heavy weight during transport, and the need of a  buddy18,22. Only when users had an exoskeleton 
at their disposal in the community, the full range of problematic scenarios and safety concerns become  apparent20. 
Such information is an important step for further exoskeleton development. Hence, the main objective of the 
present study was to assess the amount, purpose, and location of exoskeleton use in the home and community 
environment by people with complete SCI. Users’ experiences and health related effects during this period were 
studied as well.
Methods
participants. People with complete SCI who gained knowledge about the existence and availability of an 
exoskeleton through the media and who were interested in testing the potential of such an exoskeleton contacted 
the rehabilitation center of the Sint Maartenskliniek to participate in this study. The eligibility criteria have been 
described  previously10. Adults in the chronic phase (> 6 months) after a motor complete SCI (American Spinal 
Injury Association Impairment Scale (AIS) A or B) between the levels Thoracic 1 (Th1) and Lumbar 1 (L1) were 
eligible. Persons with physical characteristics that would hamper proper functioning of the exoskeleton, such as 
severe spasticity (Modified Ashworth Scale > 3), body height more than 1.90 m or less than 1.60 m, body weight 
above 100 kg, or restricted range of motion at any hip, knee or ankle joint were excluded. Other exclusion criteria 
were inability to control crutches, inability to make a transfer from a regular chair to a wheelchair without the 
use of external support, and any co-morbidity or condition that could interfere with motor learning (e.g. stroke). 
Subjects with an increased risk of adverse events, such as those with osteoporosis, fractures of the lower extremi-
ties during the previous 2 years, balance disorders, neurogenic heterotopic ossification, or pregnancy, were also 
excluded. The increased risk of adverse events was checked by the rehabilitation physician through questions. 
From participant 7 onwards, osteoporosis was tested with a dual energy X-ray absorptiometry (DEXA)-scan 
at the hip. Before participants were allowed to use the exoskeleton at home or in the community, the following 
criteria had to be met:
(1) Participants had to complete an 8-week exoskeleton training and achieve a skill level for safe home and 
community use (i.e. at least 17 final skills in the previously described Final-skills-test10).
(2) Participants were required to have a buddy who received instructions about guiding the participant during 
multiple skills, including donning and doffing, sit-to-stand, and walking. In addition, a device related error 
was simulated so that both the participant and the buddy practiced trouble shooting via a graceful collapse 
(see van Herpen et al. for a more detailed description of the trouble shooting  protocol23). This protocol was 
added to the current study from participant 7 onward, after the occurrence of a bone fracture as described 
in two case  reports23.
Equipment. The ReWalk Personal 6.0, a wearable robotic exoskeleton from ReWalk Robotics that enables 
powered hip and knee motion, was used. The exoskeleton provided user-initiated mobility through the integra-
tion of a wearable brace support, a computer-based control system, and motion sensors. The ReWalk Personal 
6.0 has a Class II FDA clearance for use both in a clinical setting and in the home and community  environment24.
protocol. Participants had no restrictions regarding the amount, purpose, or at which location they used 
the exoskeleton. For safety reasons, they were instructed not to use the exoskeleton without supervision of their 
buddy. The period of home and community use was at least two weeks with a maximum of three weeks per 
participant. The return date was agreed in advance, depending on the schedules of both the participant and the 
physical therapist. Before and after a period of home and community use, the number of steps taken was read 
from the exoskeleton software and notated. During the period of home and community use, participants filled in 
a logbook each day. If participants did not use the exoskeleton on a specific day, a short reason was given, while 
the other sections of the logbook were left blank. If participants did use the exoskeleton, the complete logbook 
was filled in (see Fig. 1). The logbook included questions regarding the performed activities with the exoskel-
eton, the amount of use, and skin integrity. Comments related to the overall experience with the exoskeleton 
and/or health related effects could be registered in the blank sections of the logbook. After the first week, the pri-
mary researcher (RD) called the participants by phone to check whether the logbook was filled in correctly and 
to monitor if they had experienced any problems. When the exoskeleton was returned to the clinic, the logbook 
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was handed in and two user experience questionnaires were completed by the participants: (1) the Dutch version 
of the Quebec User Evaluation of Satisfaction with assistive Technology scale (D-QUEST 1–5 scale)25 and (2) the 
System Usability Scale (SUS 0–100 scale)26.
outcome measures. Exoskeleton use. Exoskeleton home and community use was assessed as (1) the 
amount of use, (2) the purpose of use, and (3) the location of use. The primary outcomes for exoskeleton use 
were the total number of steps taken, total number of days of usage, and total number of sessions. The total 
number of steps was extracted from the exoskeleton software (i.e. difference in total number of steps between 
the start and the end of the period of home and community use). The total days of usage and total number of 
sessions were obtained from the logbook (i.e. a completed page in the logbook indicated that they used the 
exoskeleton that day and multiple sessions on a day were written down). In addition, the amount of use per day 
(i.e. minutes of active time, total distance covered, and maximal distance covered without rest) was estimated by 
the participants and extracted from the logbook. Per session, the purpose and location of use were derived from 
the logbook and divided into various categories for the analysis. The five categories for purpose of use were: (1) 
individual exercise, (2) participation/social event, (3) exercise and social event, (4) explore indoor usability, and 
(5) other. The definitions of these purpose categories are described in Table 1. Location of use was divided into 
four categories: (1) outdoor use, (2) in home use, (3) indoor use at location (e.g. local fitness hall or indoor park-
ing lot) and (4) mixture of use at the same day (i.e. indoor/home and outdoor). The percentage per category was 
calculated as the number of session per category divided by the total number of sessions. Reasons for non-use 
were extracted from the logbook.
Exoskeleton experience. The exoskeleton experience was assessed as the satisfaction, importance, and usability 
of different aspects of the exoskeleton. In addition, other experiences with the exoskeleton (e.g. fall or device 
error) that were recorded in the logbook were evaluated. Satisfaction was derived from the 12-item D-QUEST 
 questionnaire25 and divided into satisfaction with the assistive device (8 items), satisfaction with the service (4 
items), and overall satisfaction (average). The satisfaction (sub)scores ranged between 1 and 5, with a higher 
score indicating greater satisfaction. Item analysis of satisfaction scores was performed, in which an item score of 
1, 2 or 3 was considered  dissatisfied27. In addition, the importance of each item was analysed by calculating how 
frequent a particular item was indicated by the participants as one of the three most important items. Usability 
was derived from the 10-item SUS  questionnaire26 and evaluated as the overall usability and at item level. Each 
SUS item was scored from 0 (low usability) to 4 (high usability). The overall SUS score was calculated by multi-
plying the sum of the item scores by 2.5 and ranged between 0 and  10026, with a higher score indicating better 
usability. A mean SUS item score below 3 was considered low usability.
Describe the activities in which you have used the exoskeleton today. If you did not use the exoskeleton today, state the reason why (you do not need 
to fill out the rest of the logbook).
First, inside the house put on the exoskeleton to show it to friends. Then we walked around the house with a group of 10 people. Walked a slalom 
and made many turns. It was a wonderful feeling to walk with a group of friends. I really enjoyed it today.
How long have you used the exoskeleton today? Approximately …… 45 ……minutes
What was the total covered distance with the exoskeleton today? Approximately …… 265 ……meters
What is the longest consecutive distance you have walked with the exoskeleton today? If you have paused for more than 1 minute, this does not 
count as one consecutive distance …… 60 ……meters
How often have you put the exoskeleton on today …… one ……time(s).  Give an indication of the amount of time you had the exoskeleton on 
each time. Multiple answers are possible 1. …… 45 ……minutes 2. …………………minutes    3. …………………minutes
Have you noticed any bruises or other injuries during the ‘self-check’ today?  ☐No ☐Yes, describe what and where………………………
Tick the boxes with the activities for which you have used the exoskeleton today. Multiple answers are possible.
Take a short walk in the house Take a walk outside ☐ Open a door
☐ Small household tasks (such as making tea) ☐ Walk up a slope Walk up a sidewalk
☐ Large household tasks (such as handing the laundry) ☐ Walk down a slope Walk down a sidewalk
Social events (such as a party or go to the bar) ☐ Other inside, namely……………… ☐ Other outside, namely………………
Other remarks: After the use, no more spasm for the rest of the day. When bright sunlight shines on the remote control watch, it’s hard to read 
it. I had to guess if I selected the correct mode.
Date:………7-7-‘17……………………… Day:………1……………………….…
Figure 1.  Example of the logbook during the period of home and community use.
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Health related effects. If participants reported health related effects in the logbook, these effects were catego-
rised into positive (e.g. less neuropathic pain or improved mental health) and negative (e.g. increased pain or 
spasticity) effects. All negative effects were analysed regarding whether they resulted in non-use of the exoskel-
eton.
Statistical analysis. The distribution of the data was tested for normality using a Shapiro–Wilk test. All 
outcome measures were analysed with descriptive statistics (mean and standard deviations). In case the assump-
tion of normality was violated, median and ranges were calculated. The distribution of the amount, purpose, and 
location of exoskeleton use was reported using percentages (for grouped results) and frequencies (for individual 
results). In addition, frequency analysis of the user experiences and health related effects were reported.
Ethics approval and consent of participants. All participants gave written informed consent in accord-
ance with the Declaration of Helsinki. All research activities were carried out in accordance with the guidelines 
and regulations of the Medical Research involving Human Subjects Act (WMO) and the Netherlands Code of 
Conduct for Research Integrity. The study was approved by the medical ethics committee of Arnhem-Nijmegen 
(2016-2418) and the internal review board of the Sint Maartenskliniek.
Results
exoskeleton use. Fourteen participants had the exoskeleton at their disposal for home and community 
use. An overview of the participant characteristics is given in Table 2. Median exoskeleton use was 9 (range 
1–15) out of 16 (range 12–21) days, in which participants performed a median of 9.5 (range 1–19) sessions and 
took a median of 3,226 (range 330–28,882) steps. An overview of the amount of exoskeleton use per participant 
is given in Table 3. Per day, the estimated median active time was 46 (range 19–84) minutes, during which the 
median estimated total distance covered was 243 (range 22–1,367) meters and the median estimated maximal 
distance covered without rest was 120 (range 12–1,125) meters (Table 3). The subject-reported primary pur-
pose of exoskeleton use was for individual exercise (90 out of 121 sessions, 74% of all sessions) (Fig. 2). Other 
purposes of exoskeleton use were a combination of exercise and social event (14%, 17 sessions), participation/
social event (6%, 7 sessions), explore indoor usability (4%, 5 sessions), or other (2%, 2 sessions). The location of 
exoskeleton use was mostly outdoors (58 out of 121 sessions, 48% of all sessions) (Fig. 3). The remaining location 
of exoskeleton use was 27% (33 sessions) indoors (e.g. gym or indoor parking lot), 19% (23 sessions) combina-
tion of indoors and outdoors, and 6% (7 sessions) at home. The following factors were mentioned as reasons 
for non-use of the exoskeleton: weather conditions (i.e. storm (participant I) and snowstorm (participant M)), 
becoming a father (participant J), dependence on buddy availability (participant K), and not meeting expecta-
tions (participant L).
exoskeleton experience. The average satisfaction with the exoskeleton was rated as 3.7 ± 0.4 (D-QUEST 
total), 3.5 ± 0.4 (subscale assistive device), and 4.2 ± 0.5 (subscale service). An overview of the item analysis of 
satisfaction and importance is shown in Fig. 4. ‘Weight’, ‘Effectiveness’, ‘Ease of use’, and ‘Safety’ were most fre-







 < 100 m  ≥ 100 m Yes No
Individual exercise X X
Participation/social event X X
Exercise and social event X X
Explore indoor  usabilitya X X
Other
Table 2.  Participant characteristics. *AIS = American Spinal Injury Association Impairment Scale.
Total (N = 14)
Sex (male/female) 7/7
Age (years), median [min–max] 29 [24–49]
Time post injury (years), median [min–max] 6.25 [0.75–27]
Neurological level of SCI (thoracic), median [min–max] Th9 [Th4–L1]
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Primary: total exoskeleton use
Secondary: estimated exoskeleton usage per day 
(average)







A 20 15 (71%) 19 3,065 59 245 95
B 17 15 (88%) 15 11,562 50 296 162
C 18 12 (67%) 12 4,358 38 199 58
D 17 11 (65%) 12 7,044 79 318 80
E 18 9 (50%) 11 3,276 48 344 200
F 15 10 (67%) 10 28,882 81 1,367 1,125
G 15 10 (67%) 10 5,098 19 207 132
H 15 9 (60%) 9 3,184 53 258 120
I 15 7 (47%) 7 10,333 64 727 590
J 15 5 (33%) 5 367 21 22 12
K 17 5 (29%) 5 572 84 240 120
L 17 3 (18%) 3 655 42 183 45
M 15 2 (13%) 2 768 28 220 210
N 12 1 (8%) 1 330 40 150 75
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Figure 3.  Location of exoskeleton use during the period of home and community use.
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quently scored as dissatisfied (D-QUEST item score ≤ 3) and—at the same time—indicated as important. The 
usability of the exoskeleton was rated with a median of 72.5 [52.5–95.0]. Two SUS items had a mean SUS score 
below 3, indicating low usability (‘I needed to learn a lot of things before I could get going with this system 
(2.1 ± 1.5)’ and ‘I found the various functions in this system were well integrated (2.3 ± 0.8)’). Other experiences 
that participants recorded in the logbook were one fall and one device error (participant B). These incidences 
did not lead to health complications. Regarding the device error, the exoskeleton use was interrupted for three 
days until the error was resolved.
Health related effects. Five patients reported positive health related effects in four domains: effects on 
social and mental health (n = 5), decreased spasticity (n = 3), reduced neuropathic pain (n = 1), and increased 
range of motion of the hip and back (n = 1). Five participants reported negative health related effects, among 
which muscle or joint pain (n = 4), skin damage (n = 2), increased spasticity (n = 1), and fecal incontinence prob-
lems (n = 1). In two participants who reported shoulder pain, exoskeleton use was stopped for one day (partici-
pant H) and during the remaining period (participant N), respectively.
Discussion
This study assessed the amount, purpose, and location of exoskeleton use in the home and community environ-
ment in people in the chronic phase of motor complete SCI. In addition, users’ experiences and health related 
effects during the home and community use were studied. Fourteen people with a complete SCI used the exo-
skeleton 9 out of 16 days. The exoskeleton was mostly used for exercise purposes and social interaction. In half 
of the sessions the location of use was outdoors. Overall, participants were satisfied with the exoskeleton and 
its usability.
There was a large variation in the amount of exoskeleton use between the participants. The days of usage 
ranged from 1 to 15, during which 330 to 28,882 steps were taken. The low amount of use in some partici-
pants could be attributed to exoskeleton related factors (i.e. shoulder complaints, not meeting expectations, 
and dependence on buddy availability) or external factors (i.e. snowstorm and becoming a father). In contrast, 
more than half of the participants used the exoskeleton at least one out of two days. Because of the novelty of 
the exoskeleton and the relatively short time period of exoskeleton availability, participants probably optimally 
exploited the possibilities. Thus, although our results are likely representive for short term home and community 
use, they may be an overestimation with regard to long term exoskeleton use.
Based on the purpose and location of use, the potential of a wearable exoskeleton can be identified. The 
expected potential of an exoskeleton has previously been addressed in a qualitative study by Manns and 
 colleagues28. They found that some participants expected the best potential for outdoor exoskeleton ambula-
tion, whereas others expected better potential for functional indoor use during daily life activities (e.g. cooking 
while standing)28. Yet, only when participants have an exoskeleton at their disposal in the home and community 
setting, the full potential of an exoskeleton can be truly assessed. In the current study, all participants used the 
exoskeleton for exercise purposes and two thirds of the participants used it for social interaction, either with or 
without exercise. For exercise and social interaction purposes, the exoskeleton was used at locations with large, 
open, and smooth surfaces, either outdoors or indoors. In contrast, the exoskeleton was barely used at home. 
Indoor usability at home was explored by only four participants (and repeated once by merely one participant). 
The current findings support the general thought that an exoskeleton has a high potential to be used as an exer-
cise device and for social interaction at eye-level, but a low potential as an assistive device for supporting daily 
 activities18,20.
Despite the shortcomings of the investigated exoskeleton as an assistive device during daily life activities, 
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Satisfaction with exoskeleton use
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Figure 4.  Distribution of the satisfaction scores on the items of the Quebec User Evaluation of Satisfaction 
with Assistive Technology (D-QUEST). A satisfaction score of ‘more or less satisfied’ or less (D-QUEST ≤ 3) was 
considered dissatisfied. The numbers in brackets represent how frequent an item was indicated within the top 3 
most important items of the D-QUEST by the participants.
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participants evaluated their overall satisfaction of the exoskeleton with respect to the current use and their 
expected applications. Most participants used it as an exercise device and for social interactions and indicated 
the following aspects of improvement in order of importance: ease of use, effectiveness, safety, and weight. Ease 
of use has also been rated as most important for manual  wheelchair29,30 and walker  use29. One difference between 
wheelchair / walker use and exoskeleton use is, the requirement of a buddy during exoskeleton use, thus poten-
tially limiting the individual’s independence. Ten of the participants reported that the buddy was a hindrance, as 
has been reported in other  studies18,22. The buddy requirement presumably influenced the other three aspects of 
improvement (effectiveness, safety, and weight) as well. The comments related to ‘satisfaction with effectiveness’ 
(e.g. the degree to which the device meets one’s needs) reflected participants’ desire for independent functional 
use. The participants also commented that they felt most safe with the buddy constantly guarding them during 
use and that because of the weight (~ 27 kg) of the device, a buddy was needed for transporting the device in and 
out of their cars. Since detailed information regarding transportation was not investigated in the current study, 
future studies should investigate the implications and issues regarding transport. Nevertheless, participants also 
emphasized that there are no other devices that enable similar options for exercise or social interaction in an 
upright position. Therefore, the overall satisfaction with the exoskeleton and its usability was considered as good, 
although less need for a buddy and improved transportability is desired. For these reasons, it is important to 
investigate how the exoskeleton can be further improved with respect to the applications that users have in mind.
For application at home and in the community, two exoskeletons are currently FDA and CE approved (ReWalk 
and  Indego24,31). The main difference between these exoskeletons is that the Indego exoskeleton is modular and 
weighs  less31, which facilitates transportation. Despite this difference in modularity, both exoskeletons require 
the use of upper extremity support (i.e. crutches) for balance, are only allowed to be used with a trained buddy, 
and have the same three options for mobility (sit, stand, and  walk24,31). Although in the current study the ReWalk 
exoskeleton was investigated, we expect similar findings for other currently commercially available exoskeletons 
that rely on upper extremity points of contact with crutches for balance.
In the current study, participants with a low (Th7–12, n = 8) and high (Th1–6, n = 6) complete SCI who could 
control crutches were included, reflecting a large range of the complete SCI population. However, selection bias is 
likely, because only people with a complete SCI who were interested in exoskeleton use and who could commit to 
the exoskeleton training protocol participated. Furthermore, only participants who achieved a skill level for safe 
home and community use (i.e. at least 17 final skills in the previously described Final-skills-test10) were included. 
Therefore, the results should be interpreted with caution and are not generalizable to the whole SCI population.
In conclusion, the exoskeleton investigated in this study (ReWalk) has a good potential to be used as an 
exercise device in the home and community environment. For this purpose, participants with a motor complete 
SCI were satisfied with its use, but wished for technological improvements to reduce the need for a buddy and 
to improve the overall transportability of the device. In addition, the exoskeleton enables social interaction at 
eye-level. Therefore, the use of an exoskeleton has the potential to contribute to the physical and mental health in 
people with complete SCI. As an assistive device during daily life activities, the exoskeleton has many limitations. 
Further exoskeleton development should, thus, look at other (more functional) applications that are important 
to their potential users.
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